Alessandro Pastorino
A5023893028- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Colorectal Cancer Surgical Treatments
- Colorectal and Anal Carcinomas
- Cancer Genomics and Diagnostics
- Gastric Cancer Management and Outcomes
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Economic and Financial Impacts of Cancer
- Cancer Treatment and Pharmacology
- Gallbladder and Bile Duct Disorders
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Screening and Detection
- Health Systems, Economic Evaluations, Quality of Life
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- COVID-19 and healthcare impacts
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Immunotherapy and Biomarkers
- Advanced Radiotherapy Techniques
- BRCA gene mutations in cancer
- Global Cancer Incidence and Screening
- Telemedicine and Telehealth Implementation
- Cardiac Imaging and Diagnostics
- Renal and related cancers
- Radiomics and Machine Learning in Medical Imaging
Ospedale Policlinico San Martino
2014-2025
Australian Regenerative Medicine Institute
2023
Monash University
2023
Azienda Ospedaliera Sant'Andrea
2018-2021
Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo
2021
CTO Andrea Alesini
2020
National Cancer Research Institute
2018
Istituti di Ricovero e Cura a Carattere Scientifico
2017-2018
Azienda Sanitaria Locale N. 2 Savonese
2016
Ente Ospedaliero Ospedali Galliera
1998
Abstract Background The TOPAZ‐1 phase III trial reported a survival benefit with the anti‐programmed death cell ligand 1 (anti‐PD‐L1) durvalumab in combination gemcitabine and cisplatin patients advanced biliary tract cancer. present study investigated efficacy safety of this new standard treatment real‐world setting. Methods analysed population included unresectable, locally or metastatic adenocarcinoma treated at 17 Italian centres. primary endpoint was progression‐free (PFS), whereas...
Background Immune checkpoint inhibitors (ICIs) have revolutionised the cancer treatment landscape in last decades, improving outcome of several tumours, such as cutaneous squamous cell carcinoma (cSCC). ICIs are antibodies blocking immune pathways, cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1) with its ligand PD-L1. However, activation response can cause a broad range side effects, called immune-related adverse events (irAEs). Endocrine irAEs mainly...
Extending the interval between end of neoadjuvant chemoradiotherapy (CRT) and surgery may enhance tumor response in patients with locally advanced rectal cancer. However, data on association delaying long-term outcome who had a minor or poor are lacking.To assess large series no to CRT shorter longer waiting times short- outcomes.This is multicenter retrospective cohort study. Data from 1701 consecutive cancer treated 12 Italian referral centers were analyzed for colorectal January 2000...
Background: The decision to administer adjuvant chemotherapy (ACT) in stage II colorectal cancer (CRC) remains challenging. Clinical and histopathological criteria, even when integrated with ctDNA-based assessment of residual disease, are still suboptimal ACT benefit predictors. Immune cell infiltration has been repeatedly associated better outcome, but the prognostic value transcriptional immune signatures not assessed prospective trial cohorts a systematic way. We aimed identify signature...
To establish the concept of minimum clinically meaningful outcome (mCMO) treatment in advanced solid tumors, to its threshold and evaluate how many superiority trials new antineoplastic agents pass this threshold.We chose overall survival as primary indicator patient benefit. Four conceptually different types effect can be identified OS curves: HR, gains median OS, proportional, absolute increases at long-term OS. We postulated levels for these four parameters defining mCMO set bar three...
ObjectiveTo identify imaging markers predicting clinical outcomes to regorafenib in metastatic colorectal carcinoma (mCRC).MethodsThe RadioCORRECT study is a post hoc analysis of cohort patients with mCRC treated within the phase III placebo-controlled CORRECT trial regorafenib. Baseline and week 8 contrast-enhanced CT were used assess response by RECIST 1.1, changes sum target lesion diameters (ΔSTL), lung metastases cavitation liver density. Primary secondary objectives develop ex novo...
This cohort study examines rates of SARS-CoV-2 infection among patients with cancer receiving antitumor treatment.
Aflibercept combined with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) as second-line treatment of metastatic colorectal cancer (mCRC) significantly improved survival compared alone in the pivotal VELOUR (aflibercept vs. placebo combination irinotecan and 5-fluorouracil patients after failure an oxaliplatin-based regimen) trial. No quality-of-life assessment was performed VELOUR; therefore, ASQoP (Aflibercept Safety Quality-of-Life Program) trial designed to capture safety...
Multigene germline panel testing is recommended for Pancreatic Cancer (PC) patients; however, non-BRCA1/2 genes, the clinical utility unclear. A comprehensive multi-gene assessment in unselected Italian PC patients missing. We evaluated prevalence and impact of Pathogenic Variants (PV) 51 susceptibility genes a real-world series 422 Family History (FH), compared characteristics conducted survival analyses. 17% had PVs (70/422), mainly BRCA1/2 (4.5%, all <70 y), CDKN2A >50 ATM (2.1%). PV...
Background Universal screening of colorectal cancer (CRC) patients for Lynch syndrome (LS) through MisMatch Repair (MMR) testing is recommended. BRAFV600E mutation and/or MLH1 promoter methylation (Reflex Testing, RefT)generally rule out LS in MLH1-deficient (dMLH1) patients. We estimated the impact RefTon genetic counseling (GC) and on diagnostic yield (GT). Methods Overall, 3199 CRC were referred to our center between 2011 2021. Patients until January 2019 (n=2536) underwent universal MMR...
Multiple primary colorectal carcinomas (CRCs) synchronous, when detected approximately at the same time, or metachronous, a significant amount of time has elapsed between diagnoses can show both mismatch repair (MMR) status concordance and discordance tumors. The aim was to evaluate MMR monoinstitutional, retrospective cohort synchronous metachronous CRCs, with focus on frequency cases discordant status, explore metastatic nodal deposits. All CRCs diagnosed in our institution 2011 2023 were...